Shopping Cart
Remove All
Your shopping cart is currently empty
Enoblituzumab (Alias: TJ-271, MGA271)
Catalog No. T9901A-002 Copy Product Info
Purity: 95%
🥰Excellent
Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC).
Enoblituzumab
Copy Product Info🥰Excellent
Catalog No. T9901A-002
Alias TJ-271, MGA271
Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC).
Enoblituzumab
Cas No. 1353485-38-7
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | - | In Stock | |
| 5 mg | $483 | - | In Stock | |
| 10 mg | $692 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock | |
| 100 mg | $2,100 | - | In Stock |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:96.7% (SDS-PAGE); 98.5% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC). |
| In vitro | Enoblituzumab interacts with B7-H3, resulting in potent antibody-dependent cellular cytotoxicity (ADCC) across a broad range of cancer cells[2]. It effectively mediates ADCC against A498 cells at concentrations ranging from 0.01 ng/mL to 10 mg/mL using cynomolgus monkey peripheral blood mononuclear cells (PBMCs)[3]. |
| In vivo | In mice (mCD16-/-hCD16A+) with murine CD16 gene knocked out and transgenic for human CD16A-158F, enoblituzumab (5 mg/kg; i.v.; single dose) exhibits an estimated half-life of 249 hours with a Cmax of 43 mg/mL[3]. Exhibiting potent antitumor activity in xenograft mice models of renal cell and bladder carcinoma expressing B7-H3, enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) shows this effect[3]. |
| Synonyms | TJ-271, MGA271 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | B7-H3/CD276 |
| Molecular Weight | 145.81 kDa |
| Cas No. | 1353485-38-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Enoblituzumab | purchase Enoblituzumab | Enoblituzumab cost | order Enoblituzumab | Enoblituzumab in vivo | Enoblituzumab in vitro | Enoblituzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.